Indeed, wortmannin has been shown to increase Alzheimer-like tau phosphorylation in vivo (Liu and Wang, 2002; Xu et al., 2005) and to diminish the effect of an anti-apoptotic compound in an in vitro PD model (Limboonreung et al., 2020). The gene discussed is MAPT; the disease is Parkinson disease.